Inspire Medical's Strong 2025 Outlook And Upcoming Inspire V Launch Earns Analyst Upgrade
Inspire Medical's Strong 2025 Outlook And Upcoming Inspire V Launch Earns Analyst Upgrade
For 2024, the company expects sales of $793 million – $798 million compared to prior guidance of $788 million – $798 million and a consensus of $796.09 million.BofA Securities has upgraded Inspire Medical Systems, Inc. (NYSE:INSP) and says the company now falls in the profitable growth category.
美銀證券已經對Inspire Medical Systems, Inc.（紐約證券交易所代碼：INSP）進行了升級，並表示該公司現在屬於盈利增長類別。
Inspire Medical is expected to give its 2025 revenue guidance in early January, likely alongside its fourth-quarter results.
Inspire Medical預計將在1月初公佈其2025年的收入指導，可能還會公佈其第四季度業績。
The company has already stated that it is comfortable with the Street's consensus of $950 million in revenue for 2025.
該公司已經表示，它對華爾街共識的2025年收入爲9.5億美元感到滿意。
For 2024, the company expects sales of $793 million – $798 million compared to prior guidance of $788 million – $798 million and a consensus of $796.09 million.
該公司預計2024年的銷售額爲7.93億美元至7.98億美元，而之前的預期爲7.88億美元至7.98億美元，共識爲7.96億美元。
BofA has upgraded the stock from Neutral to Buy with a price target of $255, up from $220.
美國銀行已將該股從中性上調至買入，目標股價爲255美元，從220美元上漲。
Inspire Medical's outlook for 2025 is based on plans to hire more staff, open new centers, increase direct-to-consumer advertising, expand treatment indications, and boost capacity.
Inspire Medical對2025年的展望基於僱用更多員工、開設新中心、增加直接面向消費者的廣告、擴大治療適應症和提高產能的計劃。
Also Read: FDA Labels Inspire Medical's Sleep Apnea Nerve Stimulator Recall As Most Serious
另請閱讀：美國食品藥品管理局將Inspire Medical的睡眠呼吸暫停神經刺激器召回標記爲最嚴重
The Inspire V system, expected to make a bigger impact in the second half of 2025 after the Inspire IV to V transition, could make the procedure easier and more accessible to more doctors, including general surgeons, ENTs, and neurosurgeons.
Inspire V系統預計將在Inspire IV向V過渡後的2025年下半年產生更大的影響，它可以使包括普通外科醫生、耳鼻喉科醫生和神經外科醫生在內的更多醫生更容易接受手術。
In August, the FDA approved the Inspire V therapy system, which includes the next-generation neurostimulator and the associated Bluetooth patient remote and physician programmer.
8月，美國食品藥品管理局批准了Inspire V治療系統，其中包括下一代神經刺激器以及相關的藍牙患者遙控器和醫生編程器。
The company targets a soft launch in late 2024 and a full launch in 2025
該公司的目標是在2024年底試推出，在2025年全面推出
One major advantage of Inspire V is that it simplifies the procedure by eliminating the need to place the sensing lead, which was a more complicated part of the process.
Inspire V的一個主要優勢是，它無需放置傳感導線，從而簡化了程序，而傳感導線是過程中更爲複雜的一部分。
The analyst writes, "There are limited smid cap profitable growth stocks with a new product story in 2025 and INSP screens attractive as we look for top smid cap ideas in 2025. INSP seems on the path towards double digit margins which is when valuations tend to inflect and strategic interest increases."
這位分析師寫道：「中型股盈利成長型股票有限，2025年將推出新的產品故事，而INSP的屏幕很有吸引力，因爲我們在2025年尋找最佳的中型股創意。INSP似乎走上了通往兩位數利潤率的道路，而這時估值往往會發生變化，戰略利益會增加。」
Price Action: INSP stock is up 4.90% at $184.67 at last check Wednesday.
價格走勢：週三最後一次檢查時，INSP股價上漲4.90％，至184.67美元。
Photo by Ground Picture on Shutterstock
照片由 Shutterstock 上的 Ground Pict
- What's Going On With Lifeway Stock After Rejecting Revised Acquisition Offer From Danone?
- 拒絕達能修訂後的收購要約後，Lifeway的股票怎麼了？
